Companies / Editas Medicine, Inc.

Editas Medicine, Inc.

Nasdaq: EDITCIK 1650664CAMBRIDGE, MAeditasmedicine.com

Financials · FY2025

Revenue$40.52M
Net income$-160.06M
Total debt$48.24M
Cash$181.81M
Diluted EPS$-1.80
Shares outstanding153.6M

Ownership

153.6M shares outstanding · as of Jul 31, 2026
0.23%Insiders
Ownership
Insiders0.23%347,155
Institutions35.51%54,531,551
Public float64.27%98,701,329

% of common shares outstanding (exact, from the latest cover-page filing). Institutions are quarterly 13F snapshots; insiders reflect current officers & directors.

Insiders 4

View all →
Insider% of sharesShares
O'Neill Gilmore NeilCEOCEO · Director
0.17%263,693
Burkly LindaEVP, CHIEF SCIENTIFIC OFFICER
0.04%68,028
Parison AmySVP, Chief Financial Officer
0.01%15,434

Institutional holders 202

View all →

Activity

InsidersInstitutions
What insiders are doing in this stock (Form 4).
DateActorActionSecurityValueShares ΔPosition afterImpact
Mar 3, 2026O'Neill Gilmore Neil
CEO
SellCommon Stock$10.9K-5K
-2.00%
263,693
0.17% of shares
low
Mar 3, 2026Burkly Linda
Executive
SellCommon Stock$1.5K-749
-1.09%
68,028
0.04% of shares
low
Mar 3, 2026Parison Amy
Executive
SellCommon Stock$957-474
-2.98%
15,434
0.01% of shares
low
Mar 12, 2026O'Neill Gilmore Neil
CEO
GrantStock Option (right to buy)+1.0M
1,015,200
0.66% of shares
low
Mar 12, 2026Parison Amy
Executive
GrantStock Option (right to buy)+293K
292,856
0.19% of shares
low
Mar 12, 2026Burkly Linda
Executive
GrantStock Option (right to buy)+293K
292,856
0.19% of shares
low

5%+ ownership events

Schedule 13D / 13G
FilerStance% of classSharesDate
Vanguard Group IncPassive13G/A0
RA Capital Management, L.P.Passive13G

Securities

via CUSIP / OpenFIGI
SymbolTypeMarketCUSIPFIGI
EDIT28106W103